Maggie Yuen sold $134k of ATRC
director at AtriCure, Inc.. 3,500 shares at an average of $38.42, traded Aug 5, 2026, filed Aug 7, 2026.
Score components
- +15RoleDirector
- +11Trade size$134k at market
- +5Share of holdings soldSold 20% of holdings
- +15Cluster5 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001796057-26-000010, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 5, 2026 | SOpen-market sale Common Stock | -3,500 | $38.42 | $134k | 14,015 | Aug 7, 2026 |
Related signals
Other insiders at AtriCure, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 16Weak | AtriCure, Inc. | Salvatore Privitera Chief Technical Officer | $271k 4,519 shares | -3% | |
| 42Moderate | AtriCure, Inc. | Regina E Groves director | $288k 5,313 shares | -13% | |
| 15Weak | AtriCure, Inc. | Salvatore Privitera Chief Technical Officer | $201k 3,657 shares | -2% | |
| 26Weak | AtriCure, Inc. | Salvatore Privitera Chief Technical Officer | $408k 7,763 shares | -5% | |
| 40Moderate | AtriCure, Inc. | Karl S. Dahlquist Chief Legal Officer | $458k 9,370 shares | -10% | |
| 46Moderate | AtriCure, Inc. | Karen Prange director | $138k 3,564 shares | -14% | |
| 49Moderate | AtriCure, Inc. | Sven Wehrwein director | $946k 25,000 shares | -38% | |
| 43Moderate | AtriCure, Inc. | Justin J Noznesky Chief Mktg & Strategy Officer | $240k 6,182 shares | -6% | |
| 43Moderate | AtriCure, Inc. | Vinayak Doraiswamy Chief Scientific Officer | $233k 6,000 shares | -6% | |
| 37Weak | AtriCure, Inc. | Karen Prange director | $86k 3,000 shares | -10% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.